MX2016006645A - Composicion de un inhibidor de la transcriptasa inversa sin nucleosido. - Google Patents

Composicion de un inhibidor de la transcriptasa inversa sin nucleosido.

Info

Publication number
MX2016006645A
MX2016006645A MX2016006645A MX2016006645A MX2016006645A MX 2016006645 A MX2016006645 A MX 2016006645A MX 2016006645 A MX2016006645 A MX 2016006645A MX 2016006645 A MX2016006645 A MX 2016006645A MX 2016006645 A MX2016006645 A MX 2016006645A
Authority
MX
Mexico
Prior art keywords
composition
reverse transcriptase
nucleoside reverse
transcriptase inhibitor
inhibitor
Prior art date
Application number
MX2016006645A
Other languages
English (en)
Inventor
Michael Lowinger
S Tatavarti Aditya
Jules Marsac Patrick
J M Ploeger Kristin
J Bloom Corey
Anne BROOKHART Katherine
M Baumann John
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016006645A publication Critical patent/MX2016006645A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención abarca una composición que comprende el inhibidor de la transcriptasa inversa (``RT´´) 3-cloro-5-({1-[(4-metil-5-oxo-4, 5-dihidro-1H-1,2,4-triazol-3-iI)metiI]-2-oxo-4-(trifluorometil)-1 ,2-dihidropiridin-3-iI}oxi)benzonitrilo suficientemente mezclado en un polímero mejorador de la concentración, y procedimientos para hacer las mismas; la composición y procedimiento de la presente invención mejoran de manera significativa la biodisponibilidad del inhibidor de la RT antes mencionado, mientras mantiene la estabilidad física.
MX2016006645A 2013-11-22 2014-11-19 Composicion de un inhibidor de la transcriptasa inversa sin nucleosido. MX2016006645A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907537P 2013-11-22 2013-11-22
PCT/US2014/066281 WO2015077273A1 (en) 2013-11-22 2014-11-19 Composition of a non-nucleoside reverse transcriptase inhibitor

Publications (1)

Publication Number Publication Date
MX2016006645A true MX2016006645A (es) 2016-12-16

Family

ID=53180083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006645A MX2016006645A (es) 2013-11-22 2014-11-19 Composicion de un inhibidor de la transcriptasa inversa sin nucleosido.

Country Status (11)

Country Link
US (1) US20160287568A1 (es)
EP (1) EP3071037A4 (es)
JP (2) JP6387094B2 (es)
KR (2) KR20220158860A (es)
CN (1) CN105722392B (es)
AU (1) AU2014353177B2 (es)
BR (1) BR112016011605A8 (es)
CA (1) CA2929499C (es)
MX (1) MX2016006645A (es)
RU (2) RU2661399C1 (es)
WO (1) WO2015077273A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180081082A (ko) * 2015-12-02 2018-07-13 머크 샤프 앤드 돔 코포레이션 도라비린, 테노포비르 디소프록실 푸마레이트 및 라미부딘을 함유하는 제약 조성물
RU2729792C1 (ru) * 2019-07-29 2020-08-12 Акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" Способы повышения растворимости лекарственного средства на основе пиримидинового производного бензофенона

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20080274192A1 (en) * 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
EP1909762A2 (en) * 2005-07-28 2008-04-16 Isp Investments Inc. Amorphous efavirenz and the production thereof
EP1940782B1 (en) * 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
RU2457841C2 (ru) * 2006-02-09 2012-08-10 Мерк Шарп Энд Домэ Корп. Полимерные композиции ингибиторов сетр
GEP20125378B (en) * 2006-03-20 2012-01-10 Vertex Pharma Pharmaceutical compositions
WO2009069014A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Amorphous lamivudine and its preparation
EP3130396B1 (en) * 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
RU2435584C2 (ru) * 2009-10-28 2011-12-10 Закрытое Акционерное Общество "Фармфирма "Сотекс" Пролонгированная фармацевтическая композиция, лекарственная форма и способ ее изготовления (варианты)
PL2552902T3 (pl) * 2010-03-30 2015-10-30 Merck Canada Inc Nienukleozydowe inhibitory odwrotnej transkryptazy
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体

Also Published As

Publication number Publication date
CN105722392A (zh) 2016-06-29
RU2661399C1 (ru) 2018-07-16
AU2014353177A1 (en) 2016-05-05
JP2016537332A (ja) 2016-12-01
RU2016124545A (ru) 2017-12-27
AU2014353177B2 (en) 2018-03-15
KR20220158860A (ko) 2022-12-01
CN105722392B (zh) 2019-07-23
JP6387094B2 (ja) 2018-09-05
CA2929499C (en) 2019-01-08
KR20160079816A (ko) 2016-07-06
US20160287568A1 (en) 2016-10-06
EP3071037A4 (en) 2017-08-02
WO2015077273A1 (en) 2015-05-28
EP3071037A1 (en) 2016-09-28
KR102601617B1 (ko) 2023-11-10
CA2929499A1 (en) 2015-05-28
BR112016011605A2 (pt) 2017-08-08
JP2018193396A (ja) 2018-12-06
BR112016011605A8 (pt) 2023-04-25

Similar Documents

Publication Publication Date Title
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
NZ602670A (en) Non-nucleoside reverse transcriptase inhibitors
CL2015001655A1 (es) Compuestos derivados de ftalazin-1(2h)-ona, inhibidores selectivos de la poli(adp-ribosa) polimerasa-1; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
TN2015000313A1 (en) Chemical compounds
TW201613864A (en) Novel compounds
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
EA201690179A1 (ru) Антагонисты рецептора v1a для лечения расстройств, связанных со сдвигом фазы сна
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
MX2016006645A (es) Composicion de un inhibidor de la transcriptasa inversa sin nucleosido.
MX2018003647A (es) Espuma quimica sin enjuague que contiene brimonidina y su uso en el tratamiento de la rosacea.
PH12017501767A1 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
CL2015000348A1 (es) Uso de (s)-2-(3-aminopropil)-5-(2,5-difluorofenil)-n-metoxi-n-metil-2-fenil-1,3,4-tiadiazol-3(2h)-carboxamida (arry-520) para el tratamiento de cancer en un paciente que tiene un [aag] bajo.
何辉 et al. Advances in Concrete Water-Reducing Agents Based on Natural Polymers
정의민 BOK Monitor
SI3057580T1 (sl) Farmacevtske dozirne oblike, ki vsebujejo natrijev 1-(6-(morfolin-4-il)pirimidin-4-il)-4-(1H-1,2,3-triazol-1-il)-1H- pirazol-5-olat
Wei et al. Sorafenib combined with transarterial chemoembolization could improve the outcomes of patients with advanced hepatocellular carcinoma
EA201990671A1 (ru) Ингибиторы мутантных изоцитратдегидрогеназ и включающие их композиции и способы

Legal Events

Date Code Title Description
FG Grant or registration